KATZUNG'S BASIC AND
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is reviewing information about a newly prescribed
medication. Which characteristic best describes drug potency?
A. The maximum effect a drug can produce
B. The amount of drug required to produce a specific effect
C. The rate at which a drug is eliminated
D. The percentage of drug bound to plasma proteins
Correct Answer: B
Rationale:
Potency refers to the amount of a drug needed to produce a
given effect. A more potent drug requires a lower dose to
achieve the same response. Option A describes efficacy, which
is the maximum effect a drug can produce. Options C and D
relate to pharmacokinetic properties rather than potency.
Question 2
A patient asks why a medication is still being studied after
receiving approval for marketing. Which response by the nurse
is most accurate?
A. "Post-marketing surveillance helps identify rare adverse
effects that may not have appeared during clinical trials."
B. "Approval is granted before any human testing is completed."
,C. "Approved medications no longer require safety monitoring."
D. "Post-marketing studies are used only to determine
medication pricing."
Correct Answer: A
Rationale:
Post-marketing surveillance continues after approval to identify
uncommon or delayed adverse effects in larger and more
diverse populations. Option B is incorrect because human
testing occurs before approval. Option C is incorrect because
ongoing safety monitoring remains essential. Option D is
unrelated to the primary purpose of post-marketing
surveillance.
Question 3
A nurse is teaching a group of students about therapeutic index.
Which statement is most accurate?
A. A narrow therapeutic index indicates a larger margin of
safety.
B. A narrow therapeutic index requires careful monitoring for
toxicity.
C. Therapeutic index predicts the speed of drug absorption.
D. Therapeutic index determines whether a drug can be
administered orally.
, Correct Answer: B
Rationale:
A narrow therapeutic index means the difference between
therapeutic and toxic concentrations is small, increasing the
need for monitoring. Option A is the opposite of the correct
concept. Options C and D are unrelated to therapeutic index.
Question 4
A medication is undergoing the first administration to healthy
volunteers to assess safety and dosage ranges. Which phase of
clinical testing is occurring?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A
Rationale:
Phase I trials generally involve small numbers of healthy
volunteers and focus on safety, tolerability, and dosage. Phase II
evaluates effectiveness in patients with the disease. Phase III
involves larger patient populations to confirm effectiveness and
safety. Phase IV occurs after marketing approval.
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is reviewing information about a newly prescribed
medication. Which characteristic best describes drug potency?
A. The maximum effect a drug can produce
B. The amount of drug required to produce a specific effect
C. The rate at which a drug is eliminated
D. The percentage of drug bound to plasma proteins
Correct Answer: B
Rationale:
Potency refers to the amount of a drug needed to produce a
given effect. A more potent drug requires a lower dose to
achieve the same response. Option A describes efficacy, which
is the maximum effect a drug can produce. Options C and D
relate to pharmacokinetic properties rather than potency.
Question 2
A patient asks why a medication is still being studied after
receiving approval for marketing. Which response by the nurse
is most accurate?
A. "Post-marketing surveillance helps identify rare adverse
effects that may not have appeared during clinical trials."
B. "Approval is granted before any human testing is completed."
,C. "Approved medications no longer require safety monitoring."
D. "Post-marketing studies are used only to determine
medication pricing."
Correct Answer: A
Rationale:
Post-marketing surveillance continues after approval to identify
uncommon or delayed adverse effects in larger and more
diverse populations. Option B is incorrect because human
testing occurs before approval. Option C is incorrect because
ongoing safety monitoring remains essential. Option D is
unrelated to the primary purpose of post-marketing
surveillance.
Question 3
A nurse is teaching a group of students about therapeutic index.
Which statement is most accurate?
A. A narrow therapeutic index indicates a larger margin of
safety.
B. A narrow therapeutic index requires careful monitoring for
toxicity.
C. Therapeutic index predicts the speed of drug absorption.
D. Therapeutic index determines whether a drug can be
administered orally.
, Correct Answer: B
Rationale:
A narrow therapeutic index means the difference between
therapeutic and toxic concentrations is small, increasing the
need for monitoring. Option A is the opposite of the correct
concept. Options C and D are unrelated to therapeutic index.
Question 4
A medication is undergoing the first administration to healthy
volunteers to assess safety and dosage ranges. Which phase of
clinical testing is occurring?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A
Rationale:
Phase I trials generally involve small numbers of healthy
volunteers and focus on safety, tolerability, and dosage. Phase II
evaluates effectiveness in patients with the disease. Phase III
involves larger patient populations to confirm effectiveness and
safety. Phase IV occurs after marketing approval.
